Psilocybin does increase serotonin levels in certain brain regions, but that’s only part of the story. Its primary effect is mimicking serotonin by directly activating serotonin receptors, essentially acting as a stand-in for the real thing. This distinction matters because it means psilocybin works through a fundamentally different mechanism than antidepressants like SSRIs, which raise serotonin by preventing its reabsorption.
How Psilocybin Interacts With Serotonin
Psilocybin itself doesn’t do much in the brain. It’s a prodrug, meaning your body has to convert it into its active form, psilocin, before it has any effect. This conversion happens quickly through enzymes in the gut and liver, with psilocin levels typically peaking about two hours after you swallow a dose.
Psilocin is structurally similar to serotonin at a molecular level. Once it reaches the brain, it binds to several types of serotonin receptors with roughly equal affinity, including the 5-HT2A, 5-HT2C, and 5-HT1A subtypes. At these receptors, psilocin acts as an agonist, meaning it activates them in the same way serotonin would. The psychedelic effects (visual distortions, altered thinking, emotional shifts) come primarily from activation of the 5-HT2A receptor. When researchers block that specific receptor with an antagonist drug called ketanserin, the hallucinogenic effects largely disappear.
It Also Raises Actual Serotonin Levels
Beyond mimicking serotonin, psilocin does increase the actual concentration of serotonin floating between neurons in parts of the brain. In rat studies, psilocin at moderate doses raised extracellular serotonin levels in the prefrontal cortex to about 152% of baseline, with the peak occurring 20 to 40 minutes after administration. That’s a meaningful but moderate increase. Interestingly, the effect varies by brain region. In the nucleus accumbens, a reward-related area, psilocin raised dopamine levels instead without significantly boosting serotonin.
Psilocin also weakly blocks the serotonin transporter, which is the same protein that SSRIs target. This likely contributes to the serotonin increase, though it’s a much weaker effect than what you’d see from an SSRI.
How This Differs From SSRIs
SSRIs work by blocking serotonin’s recycling system. Normally, after serotonin is released into the gap between neurons, it gets sucked back up by the releasing neuron through a transporter protein. SSRIs plug that transporter, keeping serotonin in the gap longer so it has more time to activate receptors. SSRIs don’t directly turn on serotonin receptors themselves.
Psilocybin flips that approach. Its main action is going straight to the receptors and activating them, with only a minor effect on the transporter. This means psilocybin produces intense, acute serotonin receptor activation over a few hours rather than the slow, sustained elevation of serotonin that SSRIs produce over weeks. It also means the two can interact: long-term SSRI use can reduce the number of 5-HT2A receptors in the brain, which may blunt psilocybin’s psychedelic effects.
What Happens to Receptors Afterward
One of the more interesting effects of strong serotonin receptor activation is what happens next. After a psychedelic activates 5-HT2A receptors intensely, the brain appears to pull some of those receptors off the cell surface, a process called downregulation. Research with a related compound showed that a single dose significantly reduced 5-HT2A receptor levels in the prefrontal cortex for at least 24 hours. This is one reason tolerance to psychedelics builds quickly: with fewer receptors available, the same dose has less effect if taken again soon after.
This receptor downregulation may also be relevant to psilocybin’s potential therapeutic effects. Overactive 5-HT2A signaling has been linked to rumination and rigid thinking patterns in depression, so a temporary reduction in receptor density could help reset those circuits.
Brain Plasticity Beyond Serotonin
Recent research published in Nature Neuroscience revealed a surprising finding: psilocin promotes the growth of new neural connections through a pathway that doesn’t depend on serotonin receptors at all. Psilocin directly binds to TrkB, a receptor for a growth-promoting protein called BDNF, with an affinity roughly 1,000 times higher than conventional antidepressants. When researchers blocked the 5-HT2A receptor in mice, the plasticity-promoting effects of psilocybin remained intact even though the hallucinogenic behavior (head twitching) disappeared.
This suggests psilocybin’s effects on the brain operate through at least two separate channels: one serotonin-dependent pathway that produces the psychedelic experience, and one serotonin-independent pathway that promotes structural changes in brain cells. The therapeutic potential may rely on both.
Serotonin Syndrome Risk
Because psilocybin increases serotonin activity, a reasonable concern is whether it could trigger serotonin syndrome, a potentially dangerous condition caused by excessive serotonin signaling. On its own, psilocybin’s serotonin-raising effect is moderate enough that serotonin syndrome from psilocybin alone is not a typical clinical concern. The real risk emerges with drug combinations. Serotonin syndrome most commonly occurs when a drug that raises serotonin levels is combined with a monoamine oxidase inhibitor (MAOI), which prevents serotonin from being broken down. Combining psilocybin with other serotonin-boosting drugs that don’t involve MAOIs is considered lower risk, though not zero.